Phenylethylamines and condensed rings variants as prodrugs of catecholamines, and their use
AssigneeH. Lundbeck A/S
InventorsHåkan Vilhelm Wikström, Durk Dijkstra, Bastiaan Johan Venhuis
Life of this patent
Estimating the term…
Loading patent…
AssigneeH. Lundbeck A/S
InventorsHåkan Vilhelm Wikström, Durk Dijkstra, Bastiaan Johan Venhuis
Estimating the term…
Compounds of the general formula I wherein rings B, C, D and E may be present or not and, when present, are combined with A as A+C, A+E, A+B+C, A+B+D, A+B+E, A+C+E, A+B+C+D or A+B+C+D+E, rings B, C and E being aliphatic whereas ring D may be aliphatic or aromatic/heteroaromatic, and wherein X is —(CH2)m—, in which m is an integer 1-3, to form a ring E or, when E is absent, a group R1 bound to the nitrogen atom, wherein R1 is selected from the group consisting of a hydrogen atom, alkyl or haloalkyl groups of 1 to 3 carbon atoms, cycloalkyl(alkyl) groups of 3 to 5 carbon atoms (i.e. including cyclopropyl, cyclopropylmethyl, cyclobutyl and cyclobutylmethyl) and wherein Y is —(CH2)n—, in which n is an integer 1-3, to form a ring C or when C is absent, a group R2 bound to the nitrogen atom, wherein R2 is selected from the group consisting of a hydrogen atom, alkyl or haloalkyl groups of 1 to 7 carbon atoms, cycloalkyl(alkyl) groups of 3 to 7 carbon atoms, alkenyl or alkylnyl groups of 3 to 6 carbon atoms, arylalkyl, heteroarylalkyl having 1 to 3 carbon atoms in the alkyl moiety, whilst the aryl/heteroaryl nucleus may be substituted, provided that when rings B, C, D and E are absent NR1R2 is different from dimethylamino, N-methyl-N-ethylamino, N-methyl-N-propynyl-amino, N-methyl-N-propylamino and N-hydroxipropyl-N-methylamino, and salts thereof with pharmaceutically acceptable acids or bases are disclosed as well as the use of such compounds for the manufacturing of pharmaceutical compositions for the treatment of Parkinson's disease, psychoses, Huntington's disease, impotence, renal failure, heart failure or hypertension, such pharmaceutical compositions and methods of treating Parkinson's disease and schizophrenia.
Compounds of the following general formula If:
A compound selected from the group consisting of:
A compound having a substantially pure enantiomeric form selected from the group consisting of:
A pharmaceutical composition which contains a compound, said compound selected from the group consisting of:
A pharmaceutical composition which contains a compound, said compound selected from the group consisting of:
A method of treating Parkinson's disease in a patient in need thereof, which method comprises administering to the patient a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof, wherein said compound or pharmaceutically acceptable salt thereof is selected from the group consisting of:
Dependencies are inferred from the claim text.